Recent advances in optogenetics have opened new routes to drug discovery, particularly in neuroscience. Physiological cellular assays probe functional phenotypes that connect genomic data to patient health. Optogenetic tools, in particular tools for all-optical electrophysiology, now provide a means to probe cellular disease models with unprecedented throughput and information content. These techniques promise to identify functional phenotypes associated with disease states and to identify compounds that improve cellular function regardless of whether the compound acts directly on a target or through a bypass mechanism. This review discusses opportunities and unresolved challenges in applying optogenetic techniques throughout the discovery pipeline -from target identification and validation, to target-based and phenotypic screens, to clinical trials.
Optogenetic Tools Contribute Throughout the Development Pipeline
The essence of drug discovery is to find compounds that modulate a specific physiological process in a particular subset of cells. The challenge is that minimalist high-throughput assays often have little physiological relevance, while richer phenotypic assays are slow and expensive. Typically, hundreds of thousands, or sometimes millions, of compounds fed into a screening campaign are whittled down to a few leads. A discovery team is fortunate if one lead molecule survives clinical trials. The high attrition arises because each step of the development pipeline challenges compounds against new aspects of biology which upstream assays did not address. Recently developed and emerging optogenetic tools provide a means to improve this tradeoff between throughput and realism at each step.
Optogenetics -the optical perturbation and optical measurement of physiological processeshas several attributes that make it a useful tool for drug discovery. Optical assays have the potential for high throughput and low cost. This feature has been appreciated at least since the introduction of the fluorescent imaging plate reader (FLIPR) (see Glossary) system more than 20 years ago [1] . Where optogenetics goes beyond traditional cell-based assays is in (i) the ability to deliver temporally and spatially precise stimuli to elicit defined patterns of molecular and cellular activity, (ii) the rapid proliferation of fluorescent protein reporters for a huge diversity of molecular and physiological signals, and (iii) the ability to use genetic techniques to target stimulus and readout to specified cell types within a possibly complex multicellular milieu. These capabilities give optogenetic assays throughput and information content that transcend the limits of more traditional approaches.
An optogenetic disease signature can aid discovery throughout the development process, from target identification to clinical trials ( Figure 1, Key Figure) . For instance, optogenetic measures
Trends
Optogenetic approaches have the potential to contribute throughout the drug discovery pipeline from target identification to clinical trials.
Optogenetic assays can probe specific targets and cell types within a rich physiological context.
Optogenetic measurements in patientderived neurons can elucidate genotype-phenotype relationships and probe disease mechanisms.
The integration of optogenetics with high-throughput screening requires advances in molecular tools, instrumentation, and data analytics.
of neuronal excitability can be used first to screen for targets via CRISPR-based knockout or knockdown, then to validate the efficacy and specificity of a screening hit via comparison of its effect on knockout and wild-type cells, and finally in a clinical trial with patient stem cell-derived neurons to segregate likely responders from likely non-responders.
Optogenetics in Neuroscience Drug Discovery
The impact of optogenetics will likely be greatest in drug discovery for neuroscience. On the one hand, genetic studies are implicating an ever-widening array of mutations, ranging from rare large effect-size mutations in the epilepsies [2, 3] to common individually weak mutations in psychiatric disease [4, 5] . On the other hand, the core functions of neurons are electrical spiking and synaptic transmission. Owing to the complex nonlinear interactions of multiple ion channels within cells, and of multiple cell types within circuits, the neurophysiological consequences of newly identified mutations can almost never be predicted a priori, nor can one reliably predict how pharmacological modulation of a particular target will affect brain function overall. Even as more targets are identified, neuroscience drug discoverers are turning toward a cell-and circuit-centric phenotypic approach [6, 7] rather than focusing on specific targets.
Cell-based models provide a means to instantiate newly identified mutations in a physiological but pharmacologically addressable format, and thus are an attractive substrate for phenotypic assays. Human induced pluripotent stem cell (hiPSC) technology provides a direct link between in vitro models and real patients. Genome-editing technologies provide the ability to introduce and correct targeted mutations in human and rodent neuronal models. These rapidly improving cellular substrates hold the promise of connecting human genetics to the underlying physiology.
The weak link in this chain is the measurement: how to determine the effects of mutations and candidate therapeutics on neural function. The challenge of functional assays in neurons is severe. Electrical spiking and synaptic transmission cannot be purified or measured post hoc; they must be measured in live cells in situ. Neural firing occurs on the millisecond timescale, beyond the reach of most screening tools. State-dependent drugs bind to ion channels with affinities that vary by orders of magnitude depending upon the patterns of neural activity [8] . Feed-forward and feedback mechanisms can produce circuit-level effects that are opposite to the effects of a compound on isolated cells [9] .
Optogenetic approaches are starting to address these challenges. Recent reviews have discussed optogenetic actuators [10, 11] and reporters [12] [13] [14] in detail. In this review we discuss how optogenetics can facilitate target discovery and validation, high-throughput screening, functional phenotypic assays, safety pharmacology and toxicity, and patient stratification for clinical trials.
Optogenetics for High-Throughput Screening
Drugs and ion channels perform an intricate dance wherein the affinity of the drug depends on the state of the channel, and the dynamics of the channel depend on the binding of the drug. For instance, activity-dependent block of Na V channels is crucial for targeting analgesic action to hyperactive neurons, while sparing less active neighbors. Ideally, a targeted screen for ion channel modulators would allow one to define state-dependent selection criteria, but conventional fluorescence screens are insensitive to the details of this dance (Box 1).
Optogenetic Control of Membrane Potential Light-gated ion channels and pumps provide a robust means to modulate membrane potential rapidly and reversibly. The light-gated cation channelrhodopsins are the exemplars of this class [25, 26] . Upon illumination, they mediate modestly inwardly rectifying currents, with a reversal potential of around 0 mV. Many channelrhodopsins have been discovered and engineered, with differing action spectra [27] [28] [29] [30] [31] , kinetics [32, 33] , and ionic selectivities [34] [35] [36] .
To modulate membrane potential optically, one can pair an optogenetic actuator with an inwardly rectifying potassium channel, such as K ir 2.1 or K ir 2.3. In the dark, the K ir channel sets the cell resting potential to near the K + reversal potential, typically about À80 mV. Illumination depolarizes the cell toward 0 mV. Channels that activate within this window can be modulated in temporal patterns governed by the timecourse of illumination.
To hyperpolarize a membrane one can use light-powered inward chloride pumps (e.g., halororhodopsin [37] ), outward proton pumps (e.g., archaerhodopsin 3 [38] ) or outward sodium pumps (e.g., KR2 [35] -reporter dyes (e.g., CaRuby-Nano [43] ) or proteins (e.g., RCaMP2 [44] , jRGECO1a, and jRCaMP1a,b [45] ) have recently been introduced. Unfortunately, most proteinbased fluorescent reporters are based on GFP or spectrally similar fluorophores, and thus suffer optical crosstalk with most optogenetic actuators, in other words the light used to excite the reporter spuriously activates the actuator, or vice versa. Development of far-red fluorescent reporters remains a pressing need.
Examples of Optogenetically Enabled Screens
Voltage-gated sodium (Na V ) channels are a natural target for screening via all-optical electrophysiology ( Figure 2A ), and are of interest as targets in pain and epilepsies [46] . In HEK293 cells heterologously expressing a K ir channel and a Na V channel, a depolarizing influence can activate the Na V channel, causing a sharp voltage spike to the Na
by Na V channel inactivation and return to baseline driven by the K ir channel. Electrically spiking HEK cells have been demonstrated with Na V 1.3 [47] , Na V 1.5 [48] , Na V 1.7 [49] , and Na V 1.9. A Box 1. Ion Channel Screening Tools Several fluorescence assays have been developed for screening ion channel modulators. Typically, a static membrane voltage is set via the ionic content of the extracellular medium. Sometimes a tool compound is applied to force the channels into a particular state (e.g., veratridine for Na V channels). The response to a test compound is then monitored either via fluorescence of a voltage-sensitive dye or via modulation of the flux of a readily detected ion (e.g., Ca
2+ for Ca V channels [15] , Tl + for Na V [16] and K V [17] channels, and I À for chloride channels [18] ). Screens of this type cannot select for particular binding modes or kinetics.
Automated patch-clamp electrophysiology [19] provides accurate programming of membrane potential and readout of membrane current, and is becoming widely used in ion channel screening [20] . However, this approach becomes expensive for large-scale screens and still suffers from technical limitations, including a $17% drop-out rate of individual wells [21] and difficulty in probing channels with small overall currents. For instance, the voltage-gated sodium channels Na V 1.8 and Na V 1.9, which play an important role in mediating pain transmission, are difficult to express at sufficiently high levels for automated patch-clamp measurements [22, 23] . Automated patch-clamp measurements are typically restricted to stable cell lines, although applications in cardiomyocytes have been demonstrated [24] .
recent all-optical screen of 320 FDA-approved compounds for activity-dependent block of Na V 1.7 yielded results in close concordance with manual patch clamp ( Figure 3 ) [49] . By varying the intensity and duration of the optical stimulus pulses, one could probe subtle features of state-dependent pharmacology in a high-throughput format.
A similar approach has been used to probe the Ca V 1.3 voltage-gated calcium channel ( Figure 2B ) [50] , a potential target in Parkinson's disease [51] . Here the channel was paired with K ir 2.3 to set the resting potential, and a 'step-function' channelrhodopsin variant, ChR2 (D156A) [33] , was used to induce a slowly varying membrane potential. Channel activity was probed via a small-molecule Ca 2+ indicator, Fluo8. Although the Ca 2+ reporter was excited at a blue wavelength that also drove the channelrhodopsin, crosstalk was minimized by performing the fluorescence measurement on a timescale much shorter than that of Ca 2+ influx. The activity of Ca V channels could likely also be probed with red-shifted Ca 2+ reporters to avoid optical crosstalk.
Key Figure
Optogenetics Cyclic nucleotide-gated (CNG) cation channels are a possible target for neuropathic pain [52] . Figure 2C illustrates an optogenetic screen for the HCN2 channel [50] . Upon blue illumination, a light-activated adenylyl cyclase, bPAC [53] , produces cAMP which then activates the HCN channel. Channel activation was probed via a slow voltage-sensitive dye. Although the wavelength used to excite the dye also activated the bPAC, the dye measurement took place sufficiently rapidly that measurement-triggered bPAC activation did not affect the measurement. The HCN channels are also activated by membrane hyperpolarization, and thus optogenetic approaches could be used, in principle, to probe the voltage-dependent pharmacology of these channels.
Receptor tyrosine kinases (RTKs) are interesting targets in oncology, metabolic disorders, and neurodegeneration. However, a lack of known ligands presents a problem for screening against some RTKs. Figure 2D shows an optogenetic screen for modulators of RTK signaling [54] . Lightsensitive 'Opto-RTKs' were formed by incorporation of a light-oxygen-voltage-sensing (LOV) domain which caused dimerization and thereby activation of the RTK in the light. Downstream activation of the MAPK/ERK pathway drove the expression of a gene for a fluorescent reporter protein, and the pharmacological modulation of this response was readily detected in a highthroughput format. Remarkably, this approach worked even for RTKs with no known ligand. As in the screens of the Ca V and HCN channels, crosstalk between stimulation and readout was avoided by using a slow reporter mechanism, in this case GFP expression.
In these examples, optogenetics offers several key advantages over ligand-based activation of the target pathways. First, for rapid processes, one can achieve precise temporal synchronization across a well, and correspondingly high time-resolution in whole-well fluorescence measurements. Second, it is possible to mix cell lines with different actuators paired with spectrally distinct reporters to provide in-well controls. For instance, one could screen for compounds that have differential activation of structurally similar targets. Third, one can vary the illumination intensity across a well to perform in-well dose-response measurements. While sophisticated instrumentation is necessary to produce precise optical gradients, a simple shadow mask can divide a well between optogenetically activated and unactivated cells for an in-well reference. These benefits could be applied to many novel optogenetic screens that have not yet been implemented (Box 2).
Optogenetics for Phenotypic Screening
Following the maxim 'you get what you screen for' [74] , target-based screens identify modulators of specific targets. However, a modulator of a disease-relevant target might still make a poor drug for several reasons: (i) the hit compounds might also modulate other targets. Indeed, many neuroactive drugs developed around a nominal target turned out later to modulate other ion channels [75] .
(ii) Selective modulation of a specific target can be a poor therapeutic strategy. Dysregulated neural circuits might not contain a unique target whose modulation will restore the defective function; selective modulation of a single broadly distributed target might still cause undesirable effects in other brain regions or organs. (iii) Many effective drugs have been developed without a clear target, or that modulate multiple targets. For instance, gabapentin, pregabalin [76] , and levetiracetam [77] , all widely prescribed anti-epileptic drugs, were developed without a clear understanding of their mechanism of action. Screens that directly probe the effects of compounds on neuronal firing or synaptic transmission select for mechanisms relevant to disease biology, agnostic to the molecular target. Optogenetic assays now enable phenotypic measurements across a range of contexts relevant to neuroscience drug discovery (Figure 4 ).
Neuronal Excitability
Neuronal firing patterns arise from complex interactions of many ion channels and metabolic factors; neuronal firing converts these molecular interactions into sensations and behavior.
Box 2. Optogenetics for Novel Target-Based Screens
The power of optogenetically enabled high-throughput screens is only beginning to be realized. We give several examples of prospective screening approaches.
Gap Junctions
Gap junctions, which are electrical conduits between neighboring cells, are an interesting target in epilepsy [55] . When HEK cells are grown to confluence, they form gap junction-mediated electrical contacts. Overexpression of gap junctions can further strengthen this electrotonic coupling [56] . In syncytial monolayers of spiking HEK cells, optogenetically induced depolarizations lead to propagating waves which are sensitive to gap junction modulators [48] . Mixed coculture of HEK cells expressing either an optogenetic actuator or a fluorescent voltage indicator would provide a robust means to probe gap junction-mediated electrical conduction.
Transporters and Pumps
Membrane voltage is important in the dynamics of many transmembrane proteins beyond ion channels [57] . Indeed, every transmembrane protein that binds a charged ligand, undergoes conformational shifts, or transports charged moieties across the membrane is, in principle, susceptible to changes in membrane voltage [58] . Electrogenic transporters are sensitive to membrane voltage, as are some GPCRs [59, 60] . Voltage affects the activity of the multidrug resistance proteins MRP4 and MRP5 [61] , although there has been controversy over whether voltage also affects the multidrug efflux transporter P-gp (also known as MDR1) [62, 63] . Indeed, changes in membrane voltage have been implicated in regulating the cell cycle [64] and in the progression of cancer [65] . For these targets, optogenetic modulation of membrane potential could augment screening pipelines.
GPCRs and Other Signaling Pathways
Optogenetics can also augment drug discovery for targets where membrane voltage is not a factor. Optogenetic control has been exerted over the three major classes of GPCR-based signaling (G s [66] , G i/o [67] , and G q/11 [68] ). Chimeras of bovine rhodopsins and endogenous receptors have been used to make light-activated mimics of the adrenergic receptor (optoXR) [68] and the serotonin receptor (Rh-CT 5-HT1A ) [67] . Light-responsive soluble proteins have been coupled to the MAPK pathway, PI3K pathway, Rho GTPase signaling, and RTK signaling [69] . Broadly applicable strategies have been developed for controlling protein localization, activity, oligomerization, and secretion with light [69] . Recently, the optogenetic toolbox was further expanded with a light-controlled CRISPRa activator which can control endogenous gene expression with spatial and temporal precision [70] . These powerful capabilities are only beginning to enter drug discovery pipelines.
Target-Based Screening in Primary Cells
Target proteins can behave very differently in heterologous expression systems and in native cells because of alternative splicing, post-translational modifications, variations in trafficking, clustering, and degradation, and interactions with modulatory subunits. For instance, dynamic clustering of the soma-localized potassium channel K V 2.1 regulates its activity [71] , while trafficking of the sodium channel Na V 1.2 along the axon initial segment regulates neuronal excitability [72] . Thus, even for target-based screens, there is merit in assessing target function in its native cellular context.
A few optogenetic tools have been developed to probe the function of specific targets in a complex cellular milieu. Fluorescently labeled toxins with state-dependent binding can be used to probe the activation of native K V 2.1 ion channels [73] . FRET-based reporters can probe the activation of specific kinases, GPCRs, and other targets [13, 14] . With these tools one can perform target-based screens in native cells. There remains a strong need for improved fluorescent reporters for tracking the location and activity of specific drug targets within a complex cellular milieu.
Thus neuronal excitability is a powerful integrative phenotype for disease modeling and drug discovery. Optogenetic techniques now provide high-throughput access to this phenotype.
Optogenetic measures of neuronal excitability can be used in several contexts ( Figure 5 ) (i) Target identification: genetic perturbations, for example via CRISPR/Cas9 technology, can identify prospective drug targets that modulate neuronal excitability, or validate targets suggested by other means, for example genetic studies.
(ii) Target-based screens: comparisons of drug effects on the excitability of neurons +/À a specific target can distinguish on-target from off-target mechanisms of action. (iii) Purely phenotypic screens: comparisons of drug effects on different neuronal subtypes, for example excitatory versus inhibitory neurons, can identify compounds that have differential effects on excitability, regardless of mechanism of action.
(iv) Patient stratification: comparisons of drug effects on patient iPSC-derived neurons and on wild-type controls can seek to match patients with therapeutics or stratify patients for clinical trials -even when the underlying genetic cause of the patient's illness is not known or is poorly understood.
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Excitability
SynapƟc transmission A paired stimulus and readout are needed to perform high-throughput measures of neuronal excitability. Electric field stimulation (EFS) is a convenient means of whole-well stimulation that leaves the visible spectrum free for a variety of optogenetic readouts. EFS has been paired with whole-well measures of Ca 2+ dynamics (via GCaMP reporters) in screening format for central nervous system (CNS) [6] and dorsal root ganglion (DRG) [78] neurons, as well as with voltagesensitive dyes [75] . By using genetically encoded reporters, one could also probe the effect of test compounds on neural activity-dependent changes in other parameters such as cAMP (via ICUE3 [79] ), ATP (via Percival [80] ), or other metabolic factors.
In vivo
When EFS is applied in an imaging format, cell type-specific markers in one color channel, and broadly expressed activity markers in another channel, could be used to probe for cell typespecific effects of compounds on excitability. Such an approach could be useful, for instance, to detect compounds that differentially suppress firing in nociceptive versus non-nociceptive sensory neurons, or to detect compounds that differentially affect excitability in excitatory versus inhibitory CNS neurons.
While EFS leaves the entire optical spectrum available for functional measurements, this technique does not allow targeted stimulation of specific subsets of cells, or stimulation in precisely controlled temporal waveforms. Devoting the blue part of the spectrum to optogenetic actuation still leaves the yellow and red parts of the spectrum for imaging voltage, Ca
2+
, or other functional reporters.
Simultaneous optogenetic stimulation and readout of membrane voltage has been achieved through pairing a blue-shifted channelrhodopsin variant, CheRiff, with near-IR QuasAr voltage indicators [41] . These paired 'Optopatch' constructs enabled wide-field all-optical stimulation and readout of neural activity. Optopatch measurements have been used to probe the excitability of primary rodent and human iPSC-derived CNS [41] and sensory DRG [81] neurons. A recent application probed the excitability of human iPSC-derived motor neurons containing a mutation causal for amyotrophic lateral sclerosis (ALS) (Kiskinis et al., unpublished) .
Synaptic Transmission
Synaptic dysfunction is implicated in many neuropsychiatric and neurodegenerative diseases. The immense morphological and biochemical complexity of the synapse presents a forbidding obstacle to target-based drug development in this domain. . Owing to the low throughput of measurements slice-based measurements, these assays will likely find most use in target validation, for example via studies on genetically modified mice, and on hit validation or prioritization, where a small number of molecules can be tested for effects on the target circuit and on other brain regions. Despite these limitations on throughput, optogenetic mapping of compound effects on circuit excitability is a promising frontier for drug discovery.
Measurements In Vivo Most drugs go through tests of efficacy in rodent models before human clinical trials. Optogenetic activation of specific circuits can elicit a wide range of disease-relevant behaviors ,92] including fear [93] , aggression [94] , feeding [95] , pain [96, 97] , and sleep [98] . The temporal precision and repeatability with which these behaviors can be evoked via optogenetic stimulation provides a robust baseline against which to test the effect of perturbations in candidate target genes or to test application of candidate therapeutics, although one should keep in mind that patterns of neural activity induced by synchronous activation of large ensembles are likely to differ substantially from naturally occurring patterns. to validate the effect of a test compound on circuit dynamics. Recently developed implants that combine optogenetic stimulation with drug delivery provide a means to test compound effects in a minimally invasive manner [101] . As with measurements in acute brain slices, the low throughput of optogenetic measurements in vivo will most likely restrict applications to target and hit validation.
Optogenetics in Safety and Toxicology
Safety remains a key hurdle in drug development, and cardiac safety is of paramount concern because of the potential severity of cardiac side-effects. Traditional safety assessments require testing against the cardiac hERG channel, a common cause of off-target cardiotoxicity, followed by tests in dogs and humans [105] , combined with optogenetic pacing [106] , provide a rich functional phenotype for exploring drug effects on human cardiac activity. Similarly, the all-optical electrophysiology method can also be used for neurotoxicity studies to evaluate compound effects on neuron intrinsic excitability and synaptic transmission.
Future Directions: Optogenetics in Patient Stratification and Precision Medicine
For many diseases of the nervous system, symptoms alone poorly predict the response of a patient to a candidate therapeutic. Despite some notable successes of genetic stratification [ 4 2 5 _ T D $ D I F F ] [107] , in many instances genetics provides little additional guidance. Optogenetic measurements on patient iPSC-derived neurons provide a means to instantiate the entire genome of a patient in a physiologically relevant and pharmacologically accessible format. A likely direction of future progress will be toward patient stratification based on functional cell-based measurements. Initially this work will occur in the presence of stratification for clinical trials, although ultimately the approach may be extended to individual patients, seeking to select among many possible therapeutic options. Patient iPSC-derived neurons are most likely to replicate disease pathology for monogenic channelopathies where one can reasonably expect a robust cell-autonomous phenotype. The extent to which these cells can recapitulate complex neurodevelopmental and neurodegenerative disease processes remains a topic of active research.
Challenges for Optogenetics-Enabled Drug Discovery
Optogenetic techniques offer great promise for accelerating drug discovery. However, technical challenges remain (see Outstanding Questions). The set of spectrally compatible optogenetic actuators and reporters is limited because of the very broad action spectra of microbial rhodopsin-based actuators and the reliance of most reporters on GFP or spectrally similar proteins. Development of far-red or near-IR genetically encoded reporters would greatly expand the scope of possible applications. One would also like to see reporters for more analytes than are currently available, particularly for neurotransmitters and neuromodulators, for example GABA, glycine, dopamine, serotonin, and acetylcholine.
A further challenge is quantification. In conventional patch-clamp measurements one knows the accurate value of the membrane current and voltage. For both optogenetic stimulation and measurement, the strength of the signal depends on the expression level and trafficking of the transducer, the membrane area, and the distribution of illumination intensity. These parameters are challenging to know precisely, although there are several promising remedies. Stable transgenic cell lines can have more homogeneous expression compared to transiently transfected cells, leading to less cell-to-cell variability. Coexpression of a stable fluorescent tag can further provide a means to estimate expression level ratiometrically. The electronic excitedstate lifetime of some fluorescent reporters can also provide an expression level-independent measure of activation. We also need better instrumentation and software. Existing screening tools lack the capability for spatially and spectrally patterned illumination, and lack the temporal resolution, spatial resolution, and sensitivity needed for high-speed measurements of neuronal firing. While optical stimulation capabilities are starting to be added to existing screening platforms [ 4 2 7 _ T D $ D I F F ] [112] , these capabilities remain rudimentary. This challenge will likely be addressed through a series of instruments with differing tradeoffs in throughput and information content. A key divide is whether the instrument provides cellular resolution in a single-well format or averages over the whole well and probes multiple wells in parallel. For truly high-throughput screens (>105 compounds), the latter approach will be essential. Whole-well average measurements are most appropriate for screens on heterologously expressed proteins, for example in spiking HEK cells, or for measures of neuronal activity where the population-level response is expected to be homogeneous. Follow-up lower-throughput assays can use instruments with single-cell resolution and more complex stimulation, but with serial scanning over multiple wells. Both types of measurements have been demonstrated academically, but no company has yet undertaken the engineering to make these tools commercially available.
Finally, we need better software. Imaging a wide area at high speed and high resolution leads to prodigious data rates, typically $1 GByte/s. Specialized software pipelines are needed to store, segment, and process these data. Each discovery project must address the challenge of converting terabytes of movies into actionable screening data.
Despite these challenges, optogenetic tools are already making headway in drug discovery. Further technical advances offer the promise to bring in a new age of functional screening for diseases of cellular excitability. Traditional screening approaches have led to high rates of expensive attrition during clinical trials. By testing drugs for functional modulation of neurons, circuits, and patient-derived cells, there is reason for optimism that the initial assays will more closely approximate the patient-relevant biology. We thank the members of the Cohen Lab for their work on some of the technologies described in this manuscript.
Outstanding Questions
Can we develop red-shifted reporters for neurotransmitters and neuromodulators, which are compatible with optogenetic stimulation?
Can optogenetic measurements on human iPSC-derived neurons be used to predict patient response to drugs?
How best to parameterize and classify the complex stimulus-dependent firing patterns of neuronal disease models in vitro?
How can one attain optogenetic stimuli of precisely calibrated magnitudes, and fluorescence measurements of accurately calibrated concentrations or voltages?
